Dr. Ingo Hartung is VP of Medicinal Chemistry at Bayer AG in Berlin and in this role responsible for Bayers early research portfolio in the field of immuno-oncology. Prior to this he headed Bayers activities in discovering epigenetic probes within the Structural Genomics Consortium. Ingo joined Bayer in 2004 and led optimization projects in oncology and cardiology research at different sites for several years before assuming the role as head of Bayers microbiological chemistry group in Berlin. His research interests cover the field of oncology drug discovery, innovation in medicinal chemistry and the use of biocatalysis in life sciences. Ingo is lecturer for medicinal chemistry at the Technical University Berlin. Ingo received his PhD in organic chemistry from University of Hannover/Germany and was a post-doctoral fellow at Stanford University/US. Ingo is a member of the American Association for Cancer Research (AACR) and the Gesellschaft Deutscher Chemiker (GDCh).